Leiomyosarcoma
Therapeutic area
Oncology
Rare disease
Yes
- Definition
- An uncommon, aggressive malignant smooth muscle neoplasm, usually occurring in post-menopausal women. It is characterized by a proliferation of neoplastic spindle cells. Morphologic variants include epithelioid, granular cell, inflammatory and myxoid leimyosarcomas.
- Genetic basis
- No
- Non-human condition
- No
- Rare disease
- Yes
- Listing at source
- Listed
- Condition name
- Leiomyosarcoma
- Therapeutic area
- Oncology
- leiomyosarcoma
- Leiomyosarcomas
- leiomyosarcoma
- leiomyosarcoma (excluding uterine leiomyosarcoma)
- leiomyosarcoma - not uterine
- leiomyosarcoma, malignant
- Disease mechanisms
- Acquired
- Severity
- Severe
- Neuromuscular Disease
- Oncology
- Rheumatology
- MONDO ID
- MONDO:0005058
- Parent condition
- MONDO:0002924
Related records
Broader conditions (27)
- Cancer
- Cancer or benign tumor
- Connective and soft tissue neoplasm
- Disease
- Disease by body system or component
- Disease by etiologic mechanism
- Disease of primarily extrinsic mechanism
- Epstein-Barr virus-associated mesenchymal tumor
- Epstein-Barr virus-related tumor
- Human disease
- Malignant soft tissue neoplasm
- Mesenchymal cell neoplasm
- Muscle cancer
- Muscle tissue disorder
- Musculoskeletal system cancer
- Musculoskeletal system disorder
- Myomatous neoplasm
- Neoplasm
- Neoplastic disease or syndrome
- Post-infectious disorder
Narrower conditions (36)
- Anus leiomyosarcoma
- Bone leiomyosarcoma
- Breast leiomyosarcoma
- Central nervous system leiomyosarcoma
- Colon leiomyosarcoma
- Conventional leiomyosarcoma
- Cutaneous leiomyosarcoma
- Epithelioid leiomyosarcoma
- Esophagus leiomyosarcoma
- Extrahepatic bile duct leiomyosarcoma
- Fallopian tube leiomyosarcoma
- Gallbladder leiomyosarcoma
- Gastric leiomyosarcoma
- Granular cell leiomyosarcoma
- Heart leiomyosarcoma
- Inflammatory leiomyosarcoma
- Kidney leiomyosarcoma
- Laryngeal leiomyosarcoma
- Leiomyosarcoma of the cervix uteri
- Leiomyosarcoma of the corpus uteri
Trials (163)
- A Five-Tier, Open-Label Study of IMC-A12 in Advanced Sarcoma
- A Phase 1, First-in-human Study of OKN4395 and Pembrolizumab in Patients With Solid Tumors
- A Phase 1b, Open-Label Study Of REC-617, A Selective CDK7 Inhibitor, In Patients With Metastatic Or Unresectable RB1-Negative Leiomyosarcoma After Prior Systemic Therapy
- A Phase 2 Study of 9-ING-41Combined With Chemotherapy in Adolescents and Adults With Advanced Sarcomas
- A Phase I Trial of Combination Gemcitabine and Nab-Sirolimus in Advanced Leiomyosarcomas or Advanced Soft-Tissue Sarcomas With TSC2 or TSC1 Loss-of-function Mutations or Deletions
- A Phase II Study of Eribulin and Pembrolizumab in Soft Tissue Sarcomas
- A Study of Different Dosing Schedules of Selinexor in Sarcoma Patients
- A Study of Doxorubicin Plus Olaratumab (LY3012207) in Participants With Advanced or Metastatic Soft Tissue Sarcoma
- A Study of Ivonescimab in People With Leiomyosarcoma
- A Study of LY3435151 in Participants With Solid Tumors
- A Study of Nivolumab in Selected Uterine Cancer Patients
- A Study of OR2805, a Monoclonal Antibody Targeting CD163, Alone and in Combination With Anticancer Agents
- A Study of Rucaparib and Nivolumab in People With Leiomyosarcoma
- A Study of Trabectedin (YONDELIS) in Patients With Locally Advanced or Metastatic Liposarcoma or Leiomyosarcoma
- A Study of Trabectedin or Dacarbazine for the Treatment of Patients With Advanced Liposarcoma or Leiomyosarcoma
- A Study of Unesbulin (PTC596) in Combination With Dacarbazine in Participants With Advanced Leiomyosarcoma (LMS)
- A Study of Unesbulin in Participants With Advanced Leiomyosarcoma (LMS)
- A Study to Assess Treatment With 2 Different Dosing Schedules of Trabectidin Administered to Patients With Advanced Cancer
- A Study to Evaluate Rucaparib in Participants With Solid Tumors and With Deleterious Mutations in HRR Genes
- A Study to Evaluate Tabelecleucel in Participants With Epstein Barr Virus (EBV) Associated Diseases
Approved drugs (1)
- Trabectedin
Drugs in development (29)
- Avelumab Phase 2
- Berzosertib Phase 2
- Bevacizumab Phase 2
- Carboplatin Phase 2
- Catequentinib Phase 3
- Dacarbazine Phase 3
- Dinutuximab Phase 2
- Docetaxel Phase 2
- Doxorubicin Phase 3
- Doxorubicin hydrochloride Phase 3
- Gadolinium Phase 2
- Gemcitabine Phase 2
- Ifosfamide Phase 3
- Ipilimumab Phase 2
- Letrozole Phase 2
- Lurbinectedin Phase 2
- Mocetinostat Phase 2
- Nedisertib Phase 1
- Nivolumab Phase 2
- Olaparib Phase 2
Other linked drugs (1)
- Epirubicin